Overview of Price Target Adjustment#
BofA Securities has raised its price target for Intellia Therapeutics (NASDAQ: NTLA) from $19.00 to $20.00 while keeping a Neutral rating on the stock. Currently, shares are trading at $14.21, reflecting a 10% decline over the past week, although the stock has seen a significant increase of 64% over the past year.
Positive Trial Data#
The adjustment in price target comes after the company released phase 3 data from its HAELO trial, which focused on hereditary angioedema (HAE). The trial met its primary and key secondary goals, showing a reduction in attack rates comparable to competitors. This positive outcome supports the company's strategy in treating HAE.
Regulatory Developments#
Intellia has started a rolling submission for a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA), aiming to complete the filing in the second half of 2026. If approved, the company anticipates a potential U.S. launch in the first half of 2027. BofA views this rolling BLA, along with support for regenerative medicine, as beneficial for regulatory success.
Analyst Insights#
BofA has increased its probability of success for the HAE program from 60% to 75%, which raises the estimated contribution per share from $6 to $7. Additionally, five analysts have recently upgraded their earnings forecasts for Intellia, indicating increased confidence in the company's future. However, BofA notes that a key question remains: how much evidence of long-term effectiveness will physicians require before switching stable patients from established treatments to a new gene-editing approach?
Conclusion#
Intellia Therapeutics is making strides in genetic therapies, particularly with its CRISPR therapy, lonvo-z, which has shown promising results in reducing HAE attacks. The company plans to discuss these findings in an upcoming webcast, highlighting the importance of this advancement in the field.